Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain
  • Policy / Pricing

Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain

KFF Medicare

This analysis of available 2025 prior authorization data finds insurers denied at least 1 in 8 standard requests for prior authorization across three insurance markets: Medicare Advantage, Medicaid ma

Read full story

pharminent August 13, 2026 (Last updated: August 14, 2026)

KFF Medicare

This analysis of available 2025 prior authorization data finds insurers denied at least 1 in 8 standard requests for prior authorization across three insurance markets: Medicare Advantage, Medicaid ma

Read full story

Post navigation

Previous: Eli Lilly Files Six Lawsuits to Combat Illegal Retatrutide Black Market
Next: PTC Therapeutics Acquires Sangamo’s Fabry Disease Gene Therapy

Related Stories

  • Policy / Pricing

Trump signs order that nearly halves childhood immunisation coverage

pharminent August 11, 2026
  • Policy / Pricing

US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028

pharminent July 22, 2026
  • Policy / Pricing

UK commits to pharma IP protection in Swiss trade deal

pharminent July 16, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.